Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.
Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.
Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.
Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.
Alvotech (ALVO) has announced its upcoming Annual General Meeting (AGM) scheduled for June 25, 2025, at 09:00 a.m. CEST. The meeting will take place at Arendt & Medernach's premises in Luxembourg. Shareholders can access the complete agenda and meeting materials through Alvotech's investor relations website. The company has provided a dedicated contact for investor relations inquiries through Benedikt Stefansson, VP.
Alvogen Lux Holdings S.ár.l., Alvotech's second-largest shareholder, has acquired 95,000 shares of Alvotech (ALVO) at ISK 1,260 per share on May 20, 2025. The transaction was reported to the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). Alvogen Lux Holdings' ownership structure consists of CVC (40%), Aztiq (30%), and Temasek (20%) as its largest shareholders.
Alvotech (NASDAQ: ALVO) has signed an agreement with DNB Carnegie Investment Bank AB to provide liquidity services for its Swedish Depository Receipts (SDRs) trading on Nasdaq Stockholm. Starting May 20, 2025, DNB Carnegie will act as a liquidity provider, continuously quoting prices for Alvotech's SDRs in compliance with Nasdaq Stockholm's minimum requirements. The primary objective is to enhance SDR liquidity and minimize the spread between buying and selling prices.
Alvotech (ALVO) reported that Richard Davies, Deputy Chairman of the Board of Directors, has acquired 19,988 shares at a price of $10.18 per share on May 14, 2025. The total transaction value amounts to approximately $203,477. The transaction was filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) as part of the required disclosure for transactions of managers and closely associated persons.
Alvogen Lux Holdings S.ár.l., Alvotech's (ALVO) second-largest shareholder, has acquired 210,000 shares at ISK 1,277.38 per share. The transaction was reported through a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). Alvogen Lux Holdings' ownership structure consists of CVC (40%), Aztiq (30%), and Temasek (20%) as its largest shareholders.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, from 11:40 am to 12:10 pm EDT. A live audio webcast of the chat will be available to the public through Alvotech's investor relations website, with a replay accessible for 90 days post-event.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, at 11:40 am-12:10 pm EDT. The chat will be accessible via live audio webcast on Alvotech's investor relations website, with a replay available for 90 days post-event.
Alvotech (ALVO) announced that its Chairman and CEO, Robert Wessman, has acquired 320,000 shares of the company at a price of ISK 1,255 per share. The transaction was executed at market opening and has been reported to the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) in accordance with regulatory requirements.